Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter.
Indaptus Therapeutics Stock Up 6.1 %
Shares of Indaptus Therapeutics stock opened at $0.83 on Wednesday. The company has a market capitalization of $11.72 million, a price-to-earnings ratio of -0.49 and a beta of 1.46. Indaptus Therapeutics has a 12-month low of $0.70 and a 12-month high of $3.10. The firm’s 50-day moving average price is $0.86 and its two-hundred day moving average price is $1.12.
Analysts Set New Price Targets
Separately, Maxim Group reduced their price target on shares of Indaptus Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th.
Indaptus Therapeutics Company Profile
Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.
Recommended Stories
- Five stocks we like better than Indaptus Therapeutics
- Trading Stocks: RSI and Why it’s Useful
- GitLab: Get In While It’s Down—Big Rebound Ahead
- What is Forex and How Does it Work?
- Tesla Stock: Finding a Bottom May Take Time
- How to Invest in Biotech Stocks
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
